Hormonal
VLCKD improves glycemic profiles (fasting glucose, HbA1c, HOMA-IR) and lipid profiles (triglycerides, total cholesterol) significantly, with some improvements (glycemia, LDL) being similar to other weight loss interventions.
You can expect your blood sugar, insulin resistance, and cholesterol numbers to improve significantly on VLCKD. However, for these specific metabolic markers, the improvement is comparable to what you might get from any other effective weight loss diet, whereas fat loss is specifically better on VLCKD.
Third, although the VLCKD also resulted in a significant reduction of glycemia, HbA1c, and LDL cholesterol, these changes were similar to those obtained with other weight loss interventions.
Why this rating
Supported by meta-analysis of multiple RCTs showing consistent biochemical improvements.
Source
European Guidelines for Obesity Management in Adults with a Very Low-Calorie Ketogenic Diet: A Systematic Review and Meta-Analysis
Giovanna Muscogiuri et al. · Obesity Facts · 2021
DOI 10.1159/000515381
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →